AI Summary & Key Takeaways
AI InsightThus, it seems thatFABP-4 may be involved in the pathogenesis of COPD.
📌 3 Key Takeaways
Abstract
Background/aim: The serum fatty acid binding protein 4 (FABP-4) level increases in chronic inflammatory diseases. The present studyaimed to examine serum FABP-4 and interleukin (IL)-6 levels in patients with stable and acute exacerbation of chronic obstructivepulmonary disease (COPD) and the correlation of these markers with airflow limitation.Materials and methods: We measured serum FABP-4 and IL-6 levels in 60 COPD patients [30 stable COPD (SCOPD), and 30 acuteexacerbation of COPD (AECOPD)], and 30 healthy subjects and compared them with airflow limitation according to the COPD stagein the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) criteria, peripheral O2 saturation (SpO2), and COPDAssessment Test (CAT) score. We also tested the association between serum FABP-4 levels and some characteristics of study parameters.Results: Both serum FABP-4 and IL-6 levels increased with increasing severity of GOLD grades in SCOPD (P < 0.01 for both) andAECOPD groups (P < 0.001 and P < 0.01, respectively). It also increased in patients with AECOPD group compared with SCOPD groupin GOLD grades I-II (P < 0.01) and GOLD grades III-IV (P < 0.05). In addition, there was a significant positive correlation betweenserum FABP-4 level with IL-6, CAT score, and smoking history and inversely with FEV1 and SpO2.Conclusion: The study revealed that serum FABP-4 level was elevated with increasing GOLD grades in COPD patients, markedly inacute exacerbation phase. The increase was associated with elevated serum levels of IL-6 and severity of hypoxia. Thus, it seems thatFABP-4 may be involved in the pathogenesis of COPD.